Clinical Trial Results Bolster Novo Nordisk’s Market Position

Amidst a challenging year that includes projected adjusted revenue declines of up to 13%, Novo Nordisk is fortifying its competitive stance with compelling new clinical evidence. The Danish pharmaceutical giant recently unveiled study data that positions its oral Wegovy pill favorably against a key new rival product from Eli Lilly.

Strategic Pricing and Subscription Initiatives

Concurrent with its clinical advancements, Novo Nordisk is implementing strategic commercial measures to address pricing pressures from generics and competitors like Lilly. In India, the company has reduced prices for Wegovy and Ozempic by as much as 48%, a move aimed at securing market volume in a region with intense generic competition.

In the United States, a novel multi-month subscription program for Wegovy has been launched. Patients paying out-of-pocket can now choose from three, six, or twelve-month plans, with monthly costs ranging from $249 to $329, leading to potential annual savings of up to $1,200. CEO Mike Doustdar has characterized the current fiscal period as one of unprecedented price pressure. He emphasized, however, that the company’s priorities remain volume growth and the rollout of more effective therapies, such as the high-dose Wegovy HD formulation.

ORION Trial Shows Competitive Edge for Oral Semaglutid

Data from the ORION study, presented in early April 2026, provides an indirect treatment comparison between Novo Nordisk’s oral semaglutide (25 mg) and Lilly’s recently approved orforglipron (36 mg, brand name Foundayo). The results are clear: Wegovy tablets achieved a significantly higher mean weight reduction.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

Perhaps more striking is the disparity in tolerability. Patients receiving Lilly’s 36 mg dosage discontinued treatment due to gastrointestinal side effects at a rate approximately 14 times higher than those on oral semaglutide. In the increasingly crowded market for oral obesity therapies, this tolerability advantage could prove to be a significant commercial differentiator.

Institutional Confidence and Pipeline Catalysts

Despite a tempered annual outlook, institutional investors have shown notable confidence. In the fourth quarter, Aberdeen Group plc increased its position in Novo Nordisk by 231.4%, bringing its total holdings to 614,866 shares. At the reporting date, this stake was valued at approximately $31.3 million.

Looking ahead, a key upcoming catalyst is the FDA’s decision on CagriSema, a combination therapy of cagrilintide and semaglutide. Phase 3 trial data demonstrated a weight loss of 14.2% in adults with type 2 diabetes. A regulatory approval decision is anticipated by late 2026 or early 2027.